Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2020 September;66(3) > Minerva Gastroenterologica e Dietologica 2020 September;66(3):280-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Gastroenterologica e Dietologica 2020 September;66(3):280-9

DOI: 10.23736/S1121-421X.20.02680-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents

Marta PRIORA , Cristina REALMUTO, Simone PARISI, Maria C. DITTO, Richard BORRELLI, Clara L. PERONI, Angela LAGANÀ, Enrico FUSARO

Division of Rheumatology, Città della Salute e della Scienza, University of Turin, Turin, Italy



Beyond the classic hepatic complications, hepatitis C (HCV) infection is considered as a systemic disease, since extrahepatic manifestations become clinically evident in 40% to 70% of the patients and it can frequently include rheumatic ones. Furthermore, HCV can promote the production of several autoantibodies, thus complicating the differential diagnosis between primitive and HCV-related rheumatic disorders. The recent development of direct-acting antivirals (DAA) against HCV has revolutionized the field, reducing the damage stemming from systemic inflammatory phenomena and persistent immune activation associated with continuous HCV replication. Our review focuses on the main rheumatologic manifestations associated with chronic HCV infection as well as the impact of DAA interferon-free treatments on such extrahepatic clinical involvement.


KEY WORDS: Hepatitis C, complications; Vasculitis; Antiviral agents

inizio pagina